News & Updates

Show Multimedia Only
Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI

Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI

09 May 2023 byStephen Padilla

Use of any beta-blocker dose results in a significant decrease in mortality following acute myocardial infarction (AMI) when compared with no treatment, reports a study. Doses >25 percent to 50 percent of the currently recommended target dose (RTD) are associated with highest mortality reduction within the first year after AMI, indicating that higher doses are not required.

Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI

09 May 2023
Bisphosphonate, denosumab not linked to acute cardiovascular risk

Bisphosphonate, denosumab not linked to acute cardiovascular risk

06 May 2023

Use of oral bisphosphonate or denosumab does not appear to increase the risk of cardiovascular events (CVEs), namely acute myocardial infarction, unstable angina, cerebrovascular accident, and transient ischemic attack, in persons with incident fracture, a study has shown.

Bisphosphonate, denosumab not linked to acute cardiovascular risk

06 May 2023
Preconception HBV history linked to congenital heart disease risk in offspring

Preconception HBV history linked to congenital heart disease risk in offspring

04 May 2023

Children born to mothers who had contracted hepatitis B virus (HBV) infection before pregnancy appear to be at increased risk of congenital heart diseases (CHDs), as reported in a study.

Preconception HBV history linked to congenital heart disease risk in offspring

04 May 2023